Cefepim MIP: Uses, Dosage & Side Effects

What Is Cefepim MIP and What Is It Used For?

Cefepim MIP contains the active substance cefepime, which belongs to the fourth generation of cephalosporin antibiotics. Cephalosporins are a large family of beta-lactam antibiotics that have been in clinical use since the 1960s, and they are among the most widely prescribed antibiotics worldwide. The generations of cephalosporins reflect incremental improvements in their spectrum of activity, pharmacokinetic properties, and stability against bacterial resistance mechanisms. Fourth-generation cephalosporins, of which cefepime is the primary representative, combine the enhanced Gram-negative coverage of third-generation agents with improved Gram-positive activity and greater resistance to beta-lactamase enzymes produced by bacteria.

Cefepime exerts its bactericidal action by interfering with bacterial cell wall synthesis. Specifically, it binds to penicillin-binding proteins (PBPs), which are essential enzymes that catalyze the final transpeptidation step in the assembly of peptidoglycan, the structural polymer that gives bacterial cell walls their rigidity and shape. By inhibiting PBPs, cefepime disrupts cell wall integrity, leading to osmotic instability, cell lysis, and ultimately bacterial death. This mechanism is shared by all beta-lactam antibiotics, but cefepime has several structural advantages. Its zwitterionic molecular structure (carrying both positive and negative charges at physiological pH) allows it to penetrate the outer membrane of Gram-negative bacteria more rapidly than earlier cephalosporins, reaching the periplasmic space where PBPs are located before beta-lactamases can degrade it.

One of the most clinically important features of cefepime is its enhanced stability against AmpC chromosomal beta-lactamases. Many Gram-negative bacteria, including species of Enterobacter, Citrobacter, Serratia, and Morganella, carry chromosomal genes encoding AmpC cephalosporinases. These enzymes can be induced or derepressed during treatment with third-generation cephalosporins (such as ceftazidime or ceftriaxone), leading to the emergence of resistant mutants and clinical treatment failure. Cefepime is a poor inducer and a poor substrate for AmpC enzymes, meaning it retains its antibacterial activity even against organisms that produce high levels of these enzymes. This property gives cefepime a significant therapeutic advantage in the treatment of infections caused by AmpC-producing organisms.

The spectrum of antibacterial activity of cefepime is notably broad. Against Gram-positive organisms, cefepime is active against methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pneumoniae (including penicillin-intermediate strains), Streptococcus pyogenes, and other streptococci. Against Gram-negative organisms, it covers Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Citrobacter species, Haemophilus influenzae, Neisseria species, and critically, Pseudomonas aeruginosa. The anti-pseudomonal activity of cefepime is particularly important in the treatment of hospital-acquired infections and febrile neutropenia, where P. aeruginosa is a common and dangerous pathogen.

Cefepim MIP is indicated for the treatment of the following infections caused by susceptible organisms:

• Pneumonia: Including hospital-acquired (nosocomial) pneumonia, ventilator-associated pneumonia, and severe community-acquired pneumonia requiring parenteral therapy. Cefepime provides coverage against the most common respiratory pathogens, including S. pneumoniae, H. influenzae, K. pneumoniae, and P. aeruginosa.
• Complicated urinary tract infections: Including pyelonephritis caused by E. coli, K. pneumoniae, Proteus species, and other susceptible Gram-negative organisms. Cefepime achieves high urinary concentrations due to its renal elimination, making it particularly effective for urinary tract infections.
• Complicated intra-abdominal infections: Usually in combination with metronidazole to provide anaerobic coverage, cefepime is used for peritonitis, intra-abdominal abscesses, and biliary tract infections caused by mixed aerobic Gram-negative flora.
• Skin and soft tissue infections: Including cellulitis, wound infections, and diabetic foot infections caused by susceptible organisms, particularly when Gram-negative coverage including P. aeruginosa is required.
• Bacterial meningitis: Cefepime penetrates inflamed meninges effectively, achieving adequate cerebrospinal fluid concentrations for the treatment of meningitis caused by susceptible organisms such as S. pneumoniae, H. influenzae, and Neisseria meningitidis.
• Febrile neutropenia: Cefepime is one of the recommended first-line empirical monotherapy agents for fever in neutropenic cancer patients, as endorsed by the Infectious Diseases Society of America (IDSA) guidelines. Its broad-spectrum activity, including against P. aeruginosa, makes it suitable for this high-risk population where rapid empirical coverage of the most likely pathogens is critical.
• Bacteremia/sepsis: Cefepime is used for the treatment of bloodstream infections (bacteremia) and sepsis caused by susceptible Gram-negative organisms, either as definitive therapy guided by culture results or as part of empirical regimens.

What Should You Know Before Taking Cefepim MIP?

Contraindications

Cefepime is contraindicated in patients with a known history of severe hypersensitivity (e.g., anaphylaxis) to cefepime, any other cephalosporin antibiotic, or any of the excipients in the formulation. There is a recognized cross-reactivity between cephalosporins and penicillins, as both belong to the beta-lactam class of antibiotics. Patients who have experienced anaphylaxis or other severe allergic reactions to penicillins should not receive cefepime unless the benefit clearly outweighs the risk and appropriate monitoring is available. The estimated cross-reactivity rate between penicillins and cephalosporins varies, but recent evidence suggests it is lower than historically believed, approximately 1–2% for IgE-mediated reactions. However, a history of penicillin anaphylaxis warrants careful assessment, ideally with allergist consultation, before cephalosporin administration.

Cefepime is also contraindicated in patients with a known hypersensitivity to L-arginine, which is used as a buffer in the formulation to maintain physiological pH. This is a rare consideration but should be noted in the patient’s history.

Warnings and Precautions

Renal impairment: Since approximately 85% of cefepime is eliminated unchanged by the kidneys, dose adjustment is mandatory in patients with creatinine clearance below 50 mL/min. Failure to reduce the dose in renal impairment is the most common cause of cefepime-associated neurotoxicity. Serum creatinine should be monitored regularly during treatment, and the dose should be adjusted according to the patient’s estimated creatinine clearance using the Cockcroft-Gault formula or measured glomerular filtration rate. For patients undergoing hemodialysis, cefepime is significantly removed during the procedure, and supplemental doses should be administered after each dialysis session.

Clostridioides difficile-associated diarrhea (CDAD): Like all broad-spectrum antibiotics, cefepime carries a risk of causing C. difficile-associated diarrhea and pseudomembranous colitis. This occurs because the antibiotic disrupts the normal intestinal flora, allowing overgrowth of toxin-producing C. difficile. Symptoms may range from mild diarrhea to life-threatening colitis and can occur during treatment or weeks after discontinuation. If CDAD is suspected, cefepime should be discontinued if possible, and appropriate treatment with oral vancomycin or fidaxomicin should be initiated.

Superinfection: Prolonged use of cefepime may result in overgrowth of non-susceptible organisms, including fungi (particularly Candida species). Patients should be monitored for signs of superinfection throughout the treatment course, and appropriate measures should be taken if superinfection occurs.

Hematologic effects: Cefepime may cause transient decreases in neutrophil count, particularly during prolonged treatment courses. A positive direct Coombs test has been reported in patients receiving cefepime, which can interfere with cross-matching of blood. Rare cases of hemolytic anemia have been reported with cephalosporins as a class.

Pregnancy and Breastfeeding

Cefepime is classified as FDA pregnancy category B, meaning that animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women. Cefepime should be used during pregnancy only if clearly needed and if the potential benefit justifies any potential risk to the fetus. In clinical practice, cephalosporins as a class are generally considered to have a favorable safety profile in pregnancy, and they are among the preferred antibiotics for many infections during pregnancy when the clinical situation warrants parenteral therapy.

Cefepime is excreted into human breast milk in very low concentrations (approximately 0.5 µg/mL). While the exposure to a nursing infant is expected to be minimal, theoretical concerns include alteration of intestinal flora, direct effects on the infant, or interference with the interpretation of culture results if the infant needs to be investigated for infection. The decision to continue or discontinue breastfeeding during cefepime treatment should be made in consultation with the treating physician, weighing the benefit of breastfeeding against the potential risk to the infant.

How Does Cefepim MIP Interact with Other Drugs?

Although cefepime has fewer clinically significant drug interactions than many other antibiotic classes (it is not metabolized by cytochrome P450 enzymes and does not inhibit or induce hepatic enzymes), there are several important interactions that healthcare professionals should be aware of when prescribing this medication. These interactions can affect the safety, efficacy, or monitoring requirements of cefepime therapy.

Major Interactions

Minor Interactions

Laboratory test interference: Cefepime may cause a false-positive result in urine glucose tests that use the copper reduction method (e.g., Clinitest). Glucose-oxidase-based tests (e.g., Clinistix, Diastix) are not affected. Cefepime may also cause a positive direct Coombs test, which can interfere with blood cross-matching procedures. This should be communicated to the blood bank if the patient requires transfusion during or shortly after cefepime treatment.

IV compatibility: Cefepime should not be mixed with aminoglycoside antibiotics, vancomycin, metronidazole, or amphotericin B in the same infusion container or intravenous line due to physical or chemical incompatibility. When these drugs need to be administered concurrently, they should be given through separate intravenous lines or the line should be adequately flushed between infusions with a compatible solution such as 0.9% sodium chloride.

What Is the Correct Dosage of Cefepim MIP?

Cefepime dosing is determined by the type and severity of the infection, the suspected or confirmed causative organism, the patient’s renal function, age, and body weight. All doses should be administered by a healthcare professional in a clinical setting. The powder for injection/infusion must be reconstituted with an appropriate diluent before administration. Intravenous infusion is the preferred route for most indications and should be given over approximately 30 minutes. Extended infusion (over 3–4 hours) is increasingly used in critically ill patients to optimize pharmacodynamic exposure, as cefepime’s bactericidal activity is time-dependent (i.e., the percentage of the dosing interval that the free drug concentration exceeds the minimum inhibitory concentration [%fT>MIC] correlates with clinical efficacy).

Adults

Children

Cefepime is approved for use in children aged 2 months and older. The recommended pediatric dose is 50 mg/kg per dose administered intravenously every 8–12 hours, with the maximum single dose not exceeding 2 g. For febrile neutropenia in children, the dose is 50 mg/kg every 8 hours. For bacterial meningitis, 50 mg/kg every 8 hours is recommended. The duration of treatment is the same as for adults and depends on the type and severity of the infection. Cefepime should not be used in neonates younger than 2 months unless no alternative treatment is available, as limited safety data exist for this age group.

Elderly

No specific dose adjustment is required for elderly patients with normal renal function. However, since renal function commonly declines with age (often without a corresponding rise in serum creatinine), it is essential to estimate the creatinine clearance in elderly patients and adjust the dose accordingly. Elderly patients are also at higher risk for cefepime-associated neurotoxicity, and neurological status should be monitored closely during treatment. A lower initial dose or extended dosing interval may be considered in frail elderly patients even when calculated creatinine clearance appears borderline normal.

Missed Dose

Since cefepime is administered in a hospital setting by healthcare professionals, missed doses should be uncommon. If a dose is delayed or missed, it should be administered as soon as possible, and the regular dosing schedule should be resumed. The dose should not be doubled to compensate for a missed dose. In critically ill patients, even brief lapses in antibiotic dosing can lead to subtherapeutic drug concentrations and increased risk of treatment failure or resistance emergence, so timely administration is important.

Overdose

Overdose of cefepime, particularly in patients with renal impairment, can lead to neurotoxicity manifesting as encephalopathy (confusion, hallucinations, stupor, coma), myoclonus, seizures, and non-convulsive status epilepticus. An electroencephalogram (EEG) may show characteristic triphasic waves or generalized periodic discharges. Treatment of cefepime overdose is primarily supportive. The drug should be discontinued or the dose reduced. In severe cases, hemodialysis can effectively remove cefepime from the circulation (approximately 68% of the drug is cleared during a standard 3-hour hemodialysis session). Seizures should be treated with benzodiazepines as first-line anticonvulsant therapy. Neurological symptoms are typically reversible within 24–72 hours of dose adjustment or discontinuation.

What Are the Side Effects of Cefepim MIP?

Like all antibiotics, cefepime can cause side effects, although not everyone experiences them. The frequency and severity of side effects depend on the dose, duration of treatment, the patient’s renal function, and individual susceptibility. The side effects listed below are based on data from clinical trials and post-marketing surveillance reported in the European Medicines Agency (EMA) Summary of Product Characteristics and the FDA-approved prescribing information. Side effects are classified according to their frequency using the standard MedDRA convention.

The most clinically concerning side effects of cefepime are neurotoxicity and Clostridioides difficile-associated diarrhea. Neurotoxicity is dose-related and overwhelmingly associated with renal impairment and inadequate dose adjustment. A meta-analysis of 37 studies involving over 135,000 patients found that cefepime-associated neurotoxicity occurred in approximately 1–3% of patients overall, but the incidence increased to 10–15% in patients with renal impairment who received unadjusted doses. Symptoms typically appear within 2–5 days of treatment initiation and resolve within 24–72 hours of dose adjustment or discontinuation.

C. difficile-associated diarrhea can range from mild diarrhea to fulminant colitis with toxic megacolon, which can be life-threatening. Risk factors include advanced age, prolonged antibiotic use, use of proton pump inhibitors, and prior C. difficile infection. Any patient who develops significant diarrhea during or after cefepime treatment should be evaluated for C. difficile infection.

Allergic reactions to cefepime range from mild skin rashes (the most common hypersensitivity reaction) to severe anaphylaxis (very rare). Patients should be observed for at least 30 minutes after the first dose of cefepime, particularly if they have a history of allergic reactions to other beta-lactam antibiotics. If an allergic reaction occurs, cefepime should be discontinued and appropriate treatment initiated (e.g., epinephrine for anaphylaxis).

How Should You Store Cefepim MIP?

Proper storage of Cefepim MIP is essential to maintain its potency and safety. As a hospital-administered medication, storage is primarily the responsibility of healthcare facilities, but understanding the requirements ensures that the medication remains effective when administered.

Unopened vials: Store below 25°C (77°F) in the original packaging to protect from light. Do not freeze the dry powder. The shelf life of the unopened product is as indicated on the packaging.

Reconstituted solution: After reconstitution with the appropriate diluent (sterile water for injection, 0.9% sodium chloride for injection, or 5% dextrose for injection), the solution should be inspected visually for particulate matter and discoloration before administration. The reconstituted solution ranges from colorless to pale yellow, which is normal and does not affect potency. If the solution appears darker yellow, amber, or contains visible particles, it should not be used.

From a microbiological standpoint, the reconstituted solution should be used immediately. If not used immediately, it may be stored for up to 24 hours at 2–8°C (36–46°F) or up to 8 hours at room temperature (below 25°C / 77°F). Do not freeze the reconstituted solution.

Disposal: Any unused solution should be discarded after the recommended in-use storage period. Do not use Cefepim MIP after the expiry date printed on the packaging. Disposal should be in accordance with local regulations for pharmaceutical waste. Do not dispose of medicines via wastewater or household waste.

What Does Cefepim MIP Contain?

Active ingredient: Cefepime dihydrochloride monohydrate, equivalent to 1 g of cefepime per vial. Cefepime is a semi-synthetic, broad-spectrum, fourth-generation cephalosporin antibiotic derived from 7-aminocephalosporanic acid. Its molecular formula is C₁₉H₂₄N₆O₅S₂ (as the free base), with a molecular weight of approximately 480.6 g/mol. The dihydrochloride monohydrate salt form is used for improved stability and solubility in the powder formulation.

Excipient: L-arginine. This naturally occurring amino acid is included in the formulation as a buffering agent to adjust the pH of the reconstituted solution to approximately 4.0–6.0, which is necessary for stability and tolerability during intravenous administration. L-arginine is generally well tolerated, but patients with known hypersensitivity to L-arginine (extremely rare) should not receive this formulation.

Appearance: The powder is white to pale yellow. After reconstitution with the appropriate diluent, the resulting solution is clear and colorless to pale yellow.

Packaging: Cefepim MIP is supplied as a powder for solution for injection or infusion in single-dose glass vials. Each vial contains cefepime dihydrochloride monohydrate equivalent to 1 g of cefepime. The vials are sealed with a rubber stopper and an aluminum flip-off cap.